Global Human Cytomegalovirus Envelope Glycoprotein B Market Growth 2022-2028

SKU ID : LPI- 20259628

Publishing Date : 17-Feb-2022

No. of pages : 95

PRICE
3660
5490
7320

  • As the global economy mends, the 2021 growth of Human Cytomegalovirus Envelope Glycoprotein B will have significant change from previous year. According to our researcher latest study, the global Human Cytomegalovirus Envelope Glycoprotein B market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Human Cytomegalovirus Envelope Glycoprotein B market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
    The United States Human Cytomegalovirus Envelope Glycoprotein B market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Human Cytomegalovirus Envelope Glycoprotein B market, reaching US$ million by the year 2028. As for the Europe Human Cytomegalovirus Envelope Glycoprotein B landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
    Global main Human Cytomegalovirus Envelope Glycoprotein B players cover Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, and VBI Vaccine Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
    This report presents a comprehensive overview, market shares, and growth opportunities of Human Cytomegalovirus Envelope Glycoprotein B market by product type, application, key manufacturers and key regions and countries.
    Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
    CSJ-148
    CyMVectin
    TRL-345
    PPCM
    Cytomegalovirus Vaccine
    Others
    Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
    Infectious Disease
    Oncology
    Women's Health
    Others
    This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
    Americas
    United States
    Canada
    Mexico
    Brazil
    APAC
    China
    Japan
    Korea
    Southeast Asia
    India
    Australia
    Europe
    Germany
    France
    UK
    Italy
    Russia
    Middle East & Africa
    Egypt
    South Africa
    Israel
    Turkey
    GCC Countries
    The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
    Astellas Pharma Inc.
    Trellis Bioscience, Inc.
    Vakzine Projekt Management GmbH
    VBI Vaccine Inc
    Vical Incorporated

    Frequently Asked Questions



    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports